Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | F11 | P03951 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19263962 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL4304071 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL14477067 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL5386244 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL9850189 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL18256380 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL16756962 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL4300188 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL812510 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL12595098 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309705-A1 | NOVEL 3'-DEOXY-3'-METHYLIDENE-BETA-L-NUCLEOSIDES | NOVADEX PHARMACEUTICALS AB (SE) | 2012-12-06 | — | — | US | disclosed |
| WO-2011075052-A1 | NOVEL 3´-DEOXY-3´-METHYLIDENE- -L-NUCLEOSIDES | NOVADEX PHARMACEUTICALS AB (SE) | 2011-06-23 | — | — | WO | disclosed |
| US-7511027-B2 | Method of treating hepatitis delta virus infection | GEORGETOWN UNIVERSITY (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1284720-B1 | L-FMAU FOR THE TREATMENT OF HEPATITIS DELTA VIRAL INFECTION | UNIV GEORGETOWN (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1283211-B1 | L-Nucleosides for the treatment of hepatitis B-virus and Epstein-barr virus | UNIV GEORGIA RES FOUND (US) | 2006-06-07 | — | — | EP | disclosed |
| US-6670342-B2 | Administering a nucleoside or a nucleoside analog that suppresses the expression of the hepatitis B surface or preS1 antigen; 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uridine (L-FMAU) | GEORGETOWN UNIVERSITY | 2003-12-30 | — | — | US | disclosed |
| US-20030158149-A1 | Method of treating hepatitis delta virus infection | CASEY JOHN L (US) | 2003-08-21 | — | — | US | disclosed |
| EP-0748330-B1 | L-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B-VIRUS AND EPSTEIN-BAR VIRUS | UNIV GEORGIA RES FOUND (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1284720-A2 | METHOD OF TREATING HEPATITIS DELTA VIRAL INFECTION | Georgetown University (US) | 2003-02-26 | — | — | EP | disclosed |
| EP-1283211-A2 | L-Nucleosides for the treatment of hepatitis B-virus and Epstein-barr virus | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2003-02-12 | — | — | EP | disclosed |
| US-20020160980-A1 | Method of treating hepatitis delta virus infection | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC | 2002-10-31 | — | — | US | disclosed |
| WO-2001072294-A2 | METHOD OF TREATING HEPATITIS DELTA VIRAL INFECTION | GEORGETOWN UNIVERSITY (US) | 2001-10-04 | — | — | WO | disclosed |
| US-5808040-A | VIRICIDES | YALE UNIVERSITY (US) | 1998-09-15 | — | — | US | disclosed |
| US-5753789-A | Oligonucleotides containing L-nucleosides | YALE UNIVERSITY (US) | 1998-05-19 | — | — | US | disclosed |
| US-5587362-A | VIRICIDES FOR HEPATITIS VIRUS AND EPSTEIN-BAR VIRUS | UNIV. OF GA RESEARCH FOUNDATION (US) | 1996-12-24 | — | — | US | disclosed |
| US-5567688-A | ADMINISTERING SPECIFIED ENANTIOMORPH TO HUMAN INFECTED WITH HEPATITIS B VIRUS | UNIV. OF GA RESEARCH FOUNDATION (US) | 1996-10-22 | — | — | US | disclosed |
| US-5565438-A | L-nucleosides for the treatment of epstein-bar virus | UNIVERSITY OF GA RESEARCH FOUNDATION (US) | 1996-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158149-A1 | Method of treating hepatitis delta virus infection | NSUN3, METTL3, METAP1 | PTPN1 1693/4885USP2 4049/4885POLB 1121/4885 |
| US-20020160980-A1 | Method of treating hepatitis delta virus infection | NSUN3, METTL3, METAP1 | PTPN1 1693/4885USP2 4049/4885POLB 1121/4885 |
| US-20120309705-A1 | NOVEL 3'-DEOXY-3'-METHYLIDENE-BETA-L-NUCLEOSIDES | ENTPD5, MTAP, SLC29A1 | PTPN1 4437/4885USP2 4234/4885POLB 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.